France
Global Morpho Pharma, founded in 2018, positions itself as a pivotal player in the Manufacturing and Pharmaceutical industries. Headquartered in France, the company distinguishes itself as a turnkey technology and service provider specializing in the production and distribution of medical radioisotopes. Their focus on innovation is evident in their development of state-of-the-art equipment and the construction of efficient supply chains to facilitate the manufacturing and sourcing of non-carrier-added Lu-177 and other critical radioisotopes.
With a mission to enhance the accessibility and security of medical radioisotope supplies globally, Global Morpho Pharma is strategically positioned to meet the demands of the expanding nuclear medicine ecosystem. Despite showing promising traction in improving patient outcomes, the company has not yet disclosed any recent investment activities or partners. This could represent an untapped opportunity for investors looking to capitalize on a burgeoning market with significant growth potential.
